Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma

Author(s): Pei-pei Ren, Ming Li, Tian-fang Li, Shuang-yin Han*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 14 , 2017

Become EABM
Become Reviewer
Call for Editor


Glioblastoma (GBM) is one of the most devastating brain tumors with poor prognosis and high mortality. Although radical surgical treatment with subsequent radiation and chemotherapy can improve the survival, the efficacy of such regimens is insufficient because the GBM cells can spread and destroy normal brain structures. Moreover, these non-specific treatments may damage adjacent healthy brain tissue. It is thus imperative to develop novel therapies to precisely target invasive tumor cells without damaging normal tissues. Immunotherapy is a promising approach due to its capability to suppress the growth of various tumors in preclinical model and clinical trials. Adoptive cell therapy (ACT) using T cells engineered with chimeric antigen receptor (CAR) targeting an ideal molecular marker in GBM, e.g. epidermal growth factor receptor type III (EGFRvIII) has demonstrated a satisfactory efficacy in treating malignant brain tumors. Here we summarize the recent progresses in immunotherapeutic strategy using CAR-modified T cells oriented to EGFRvIII against GBM.

Keywords: EGFRvIII, chimeric antigen receptor, adoptive cell therapy, glioblastoma.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 30 May, 2017
Page: [2113 - 2116]
Pages: 4
DOI: 10.2174/1381612823666170316125402

Article Metrics

PDF: 67